As of this morning, 7 analysts have lowered their 12-month price target, and two analysts have changed their rating on the stock. This concept is all about the future of our industry and Edison is today’s cannabis brand.”. PAX Labs does not manufacture, produce or sell cannabis.
PAX is a leader in the design and development of premium app-controlled vaporization technologies and devices, for cannabis flower and concentrates. Join our mailing list to receive the latest news and updates from the Green Market Report.
MONCTON, NB, May 15, 2018 /CNW/ – Organigram Holdings Inc. (TSX VENTURE:OGI) (OTCQB:OGRMF) (the “Company” or “Organigram”), a leading licensed producer of medical marijuana based in Moncton, New Brunswick today unveiled their Phase 1 branding strategy for the adult recreational market in Canada. Account Amendment - Update your personal information. Contributing original content and curating quality news on only the most promising cannabis companies and the most influential investors.
PAX Labs does not manufacture, produce or sell cannabis. Now, Organigram says, “After reviewing perception around our Trailer Park Buds brand with Health Canada, the Corporation is making some changes to its newly launched brand and logo. Raymond James maintained its price target of C$5.00 and their Market Perform rating. Step into the Organigram production facility in 360 degrees. © 2020 Organigram Holdings Inc. - All rights reserved.
Longer-term, the Corporation is exploring options for a permanent logo and brand name combination for its large-format value brand. The pods will be filled onsite at Organigram's Moncton facility at the Company's Phase 5 refurbishment.
MONCTON, NB, June 7, 2019 /PRNewswire/ – Organigram Holdings Inc. (NASDAQ: OGI) (TSXV: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis and extract-based products, is pleased to announce it has been selected as one of the four Canadian launch partners of PAX Era, the premium oil vaporizer created by PAX Labs, Inc., a leading consumer technology brand in the design and development of premium vaporizers for dry flower and concentrates, when concentrates become legal in Canada later this year. The agreement with PAX reflects Organigram's own strategic commitment to growth and leadership through technology-driven innovation.
Before proceeding, we'll need to confirm you're of legal age in your province of residence. Our recreational brand strategy incorporates the best of what we know about our current and potential customers, the industry and opportunities for growth, and the production of our premium products. Social Service - Please complete if you receive social services from a shelter, hostel or similar institution. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Co., Ankr Organics, Trailer Park Buds and Trailblazer. Much like Organigram’s own Edison Cannabis Co. brand, the PAX portfolio features disruptive, industry-leading technology, on course to redefine the experience of vaping in Canada – and around the world. EBITDA is expected to come in at C$7.7 million and C$23.7 million for FY20 and FY21 respectively, down from C$8.4 million and C$69.8 million.
Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Writedowns were also material on the indefinite delay of Phase 4c, worth C$37.7m, with capacity now estimated to be 19 tons versus the 24 tons of capacity anticipated before the write-down.
Welcome to The Deep Dive, where we focus on providing investors of Canadian junior stock markets the knowledge they need to make smart investment decisions. Stifel changed their FY20 and FY21 estimates as well, with a new forecast of C$84.9 million and C$165.3 million in revenue, respectively, down from their previous forecasts of C$108.2 million and C$203.2 million.
Canaccord Genuity cut their price target to C$3.00 from C$5.00, while reiterating their Speculative Buy rating on Organigram while also lowering their estimates.